Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Clovisâ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovisâ regulatory and commercialization paths. Clovis believes this approach to precision medicineâto deliver the right drug to the right patient at the right timeârepresents the future of cancer therapy.
Source
